Search

Your search keyword '"O'Reilly, E.M."' showing total 18 results
Start Over Author "O'Reilly, E.M."
18 results on '"O'Reilly, E.M."'

1. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Author

Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O'Reilly, E.M., Hackert, T., Golan, T., Prager, G., Haustermans, K., Vogel, A., and Ducreux, M.

Subjects
*PANCREATIC cancer, *DIAGNOSIS, *RISK assessment, *THERAPEUTICS
Abstract

• The guideline covers diagnosis, staging, risk assessment, treatment, disease monitoring and follow-up. • The multidisciplinary expert author group is from different institutions and countries in Europe, Asia and the USA. • Recommendations are based on available scientific data and the authors' collective expert opinion. • ESMO-MCBS and ESCAT scores provide levels of evidence for treatment choices, including targeted therapies. • In clinical practice, all recommendations provided need to be discussed with patients in a shared decision-making approach. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. 323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3.

Author

Macarulla Mercade, T., Pazo Cid, R.A., Womack, M., Cubillo Gracian, A., Zervoudakis, A., Hatoum, H., Chung, V., Patel, A., Paulson, A.S., Pant, S., O'Reilly, E.M., Hubner, R., Van Cutsem, E., Bekaii-Saab, T., Zhang, L., Li, J., Chen, H., Maxwell, F., Wainberg, Z.A., and Melisi, D.

Subjects
*PANCREATIC duct, *SUBGROUP analysis (Experimental design), *GEMCITABINE, *ADENOCARCINOMA, *METASTASIS
Published
2024
Full Text
View/download PDF

7. Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)☆.

Author

Cohen, R., Shi, Q., Meyers, J., Jin, Z., Svrcek, M., Fuchs, C., Couture, F., Kuebler, P., Ciombor, K.K., Bendell, J., De Jesus-Acosta, A., Kumar, P., Lewis, D., Tan, B., Bertagnolli, M.M., Philip, P., Blanke, C., O'Reilly, E.M., Shields, A., and Meyerhardt, J.A.

Subjects
*COLON cancer prognosis, *COLON cancer diagnosis, *METASTASIS, *LYMPH node cancer, *TUMOR grading, *PROGRESSION-free survival
Abstract

In colon cancer, tumor deposits (TD) are considered in assigning prognosis and staging only in the absence of lymph node metastasis (i.e. stage III pN1c tumors). We aimed to evaluate the prognostic value of the presence and the number of TD in patients with stage III, node-positive colon cancer. All participants from the CALGB/SWOG 80702 phase III trial were included in this post hoc analysis. Pathology reports were reviewed for the presence and the number of TD, lymphovascular and perineural invasion. Associations with disease-free survival (DFS) and overall survival (OS) were evaluated by multivariable Cox models adjusting for sex, treatment arm, T-stage, N-stage, lymphovascular invasion, perineural invasion and lymph node ratio. Overall, 2028 patients were included with 524 (26%) TD-positive and 1504 (74%) TD-negative tumors. Of the TD-positive patients, 80 (15.4%) were node negative (i.e. pN1c), 239 (46.1%) were pN1a/b (<4 positive lymph nodes) and 200 (38.5%) were pN2 (≥4 positive lymph nodes). The presence of TD was associated with poorer DFS [adjusted hazard ratio (aHR) = 1.63, 95% CI 1.33-1.98] and OS (aHR = 1.59, 95% CI 1.24-2.04). The negative effect of TD was observed for both pN1a/b and pN2 groups. Among TD-positive patients, the number of TD had a linear negative effect on DFS and OS. Combining TD and the number of lymph node metastases, 104 of 1470 (7.1%) pN1 patients were re-staged as pN2, with worse outcomes than patients confirmed as pN1 (3-year DFS rate: 65.4% versus 80.5%, P = 0.0003; 5-year OS rate: 87.9% versus 69.1%, P = <0.0001). DFS was not different between patients re-staged as pN2 and those initially staged as pN2 (3-year DFS rate: 65.4% versus 62.3%, P = 0.4895). Combining the number of TD and the number of lymph node metastases improved the prognostication accuracy of tumor-node-metastasis (TNM) staging. • TD are observed in one-quarter of stage III colon cancers. • TD are associated with worse prognosis in stage III colon cancer, regardless of the lymph node substage. • TD should be considered as a quantitative parameter since their number has a prognostic impact. • Adding the number of TD to the count of lymph node metastases improves the prognostication accuracy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. 1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC).

Author

Schram, A., Macarulla, T., Cleary, J., Neuzillet, C., Arnold, D., Reiss, K.A., Bekaii-Saab, T., Rodon, J., Goto, K., Rha, S.Y., Duruisseaux, M., Leighl, N., Weinberg, B.A., Al-Hallak, M.N., Joe, A.K., Adeyemi, S., Wasserman, E., Koeman, K-J., Drilon, A., and O'Reilly, E.M.

Subjects
*BISPECIFIC antibodies, *PANCREATIC duct, *NEUREGULINS, *ADENOCARCINOMA
Published
2023
Full Text
View/download PDF

9. 597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance).

Author

Weiser, M., Shi, Q., Chang, G.J., Hakki, L., Goldberg, J., Auer, R., Gollub, M., Saltz, L., Musher, B.L., Al baghdadi, T., Farma, J., George, T., Colgrove, B., Nelson, G., O'Reilly, E.M., Shergill, A., Meyerhardt, J., Mamon, H., and Schrag, D.

Subjects
*NEOADJUVANT chemotherapy, *RECTAL cancer, *CHEMORADIOTHERAPY, *ABDOMINOPERINEAL resection
Published
2023
Full Text
View/download PDF

10. LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET).

Author

Chan, J., Geyer, S., Ou, F-S., Knopp, M., Behr, S., Zemla, T., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Trikalinos, N., Konda, B., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M.H., O'Reilly, E.M., and Meyerhardt, J.A.

Subjects
*NEUROENDOCRINE tumors, *PLACEBOS
Published
2023
Full Text
View/download PDF

12. 1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer.

Author

Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla Mercade, T., Hall, M.J., Park, J.O., Hochhauser, D., Arnold, D., Oh, D-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E.M., Bordia, S., McGuinness, D., Cui, K.Y., Locker, G., and Kindler, H.

Subjects
*PANCREATIC cancer, *METASTASIS, *BRCA genes, *OLAPARIB, *GERM cells, *GENETIC mutation, *METASTATIC breast cancer
Published
2021
Full Text
View/download PDF

13. 1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer.

Author

Arnold, D., Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla Mercade, T., Hall, M.J., Park, J.O., Hochhauser, D., Oh, D-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E.M., Bordia, S., McGuinness, D., Cui, K.Y., Locker, G., and Kindler, H.

Subjects
*PANCREATIC cancer, *METASTASIS, *BRCA genes, *OLAPARIB, *GERM cells, *GENETIC mutation, *METASTATIC breast cancer
Published
2021
Full Text
View/download PDF

14. 1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial.

Author

Hochhauser, D., Kindler, H., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M.J., Park, J.O., Arnold, D., Oh, D-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O'Reilly, E.M., McGuinness, D., Cui, K., Schlienger, K., Locker, G., and Golan, T.

Subjects
*PANCREATIC cancer, *METASTASIS, *BRCA genes, *OLAPARIB, *GERM cells, *GENETIC mutation, *METASTATIC breast cancer
Published
2020
Full Text
View/download PDF

16. Longitudinal follow-up of a prospective phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma reveals distinct patterns of survivorship.

Author

Datta, J., McIntyre, C.A., Chou, J., Askan, G., Drebin, J.A., Capanu, M., Balachandran, V.P., D'Angelica, M.I., Iacobuzio-Donahue, C., Basturk, O., Jarnagin, W.R., Kingham, T.P., Allen, P.J., and O'Reilly, E.M.

Subjects
*FOLLOW-up studies (Medicine), *OXALIPLATIN
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results